Monitor the EHA 2026 poster presentation on June 13, 2026, for additional detail on immunogenicity and potential partner interest. The next catalyst is the regulatory filing for clinical testing — no date provided. Given the early stage, this is not a near-term revenue event; the stock may see modest trading interest around the EHA presentation.
Price Chart
Executive Summary
Evaxion announced new preclinical data for its off-the-shelf AML vaccine EVX-04, demonstrating complete expression in human cells, immune recognition/activation, and targeted cell-killing across diverse human immune profiles. The data will be presented at EHA 2026 Congress on June 13, 2026, and the company is preparing a regulatory filing for clinical testing. This is positive but early-stage, with no revenue or timeline to clinic.
Key Facts
- EVX-04 is an off-the-shelf therapeutic vaccine for acute myeloid leukemia developed using the AI-Immunology™ platform.
- Preclinical data shows EVX-04 is successfully expressed, secreted in human cells, and induces specific immune responses and targeted cell-killing.
- Data will be presented at the EHA 2026 Congress in Stockholm, Sweden on June 13, 2026.
- The company is preparing a regulatory filing to begin clinical testing, but no timeline for an IND/CTA or first-in-human study was provided.
- Evaxion is a clinical-stage TechBio company with a market cap of ~$32M and no disclosed revenue from approved products.
Financial Impact
No financial figures disclosed. The company is pre-revenue and at the preclinical stage for EVX-04.
Risk Factors
- EVX-04 is still at the preclinical stage; clinical failure risk remains high.
- Evaxion has a small market cap (~$32M) and may require additional capital to fund clinical development.
- AML treatment landscape is competitive with existing therapies and other vaccine approaches.
- No timeline for a regulatory filing was disclosed, creating uncertainty on the next catalyst.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310196 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $3.07 $3.21 | ▲ +4.56% | ▲ +4.45% | $3.20 (+4.23%) |
Sep 4, 2026 28d ago | 6-K | $3.12 $3.07 | ▲ +1.60% | ▲ +0.39% | $3.20 (−2.56%) |
Aug 20, 2026 6w ago | 6-K | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.20 (−2.44%) |
Aug 20, 2026 6w ago | Press Release | $3.28 $3.15 | ▼ −3.96% | ▼ −5.08% | $3.20 (−2.44%) |
Aug 17, 2026 6w ago | 6-K | $3.13 $3.40 | ▲ +8.63% | ▲ +9.82% | $3.20 (+2.24%) |
Aug 14, 2026 7w ago | 6-K | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.20 (−4.19%) |
Aug 14, 2026 7w ago | Press Release | $3.34 $3.31 | ▼ −0.90% | ▲ +0.47% | $3.20 (−4.19%) |
Jul 17, 2026 11w ago | 6-K | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.20 (+4.07%) |
Jul 17, 2026 11w ago | Press Release | $3.08 $3.05 | ▼ −0.81% | ▼ −0.13% | $3.20 (+4.07%) |
Jul 13, 2026 11w ago | 6-K | $3.02 $3.08 | ▲ +1.82% | ▲ +2.61% | $3.20 (+5.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access